GlassScriptPhysician profile
Anne Jablonski
NPI 1669134821
$6,122.12
in general payments reported to CMS, 2019-2025
17 companies · $1,537 in 2025
The $1,537 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $68.96 · 2022: $46.96 · 2023: $1,967 · 2024: $2,502 · 2025: $1,537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,006.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,006.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,907.69 | 2023-2025 | Wegovy, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,558.77 | 2023-2025 | Jardiance |
| Lilly USA, LLC | $398.49 | 2023-2024 | Zepbound, Mounjaro, Jardiance |
| Sanofi-Aventis U.S. LLC | $386.22 | 2023-2025 | |
| Dexcom, INC. | $293.14 | 2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Amgen INC. | $242.19 | 2024-2025 | Evenity |
| Beta Bionics, INC. | $210.59 | 2023 | Ilet Bionic Pancreas |
| Mannkind Corporation | $177.26 | 2023 | V-Go, Afrezza |
| Insulet Corporation | $175.00 | 2025 | Omnipod |
| Ascensia Diabetes Care US INC. | $174.61 | 2024-2025 | |
| Medtronic, INC. | $170.29 | 2021-2025 | Mycarelink |
| Cequr Corporation | $163.38 | 2025 | Cequr Simplicity |
| Alkermes, INC. | $98.71 | 2025 | Aristada, Aristada Initio |
| Sequel Med Tech, LLC | $78.00 | 2025 | Twiist |
| Abbvie INC. | $46.96 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $26.35 | 2024 | |
| Currax Pharmaceuticals LLC | $14.47 | 2024 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Jablonski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.